D. Yu

发表

Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

J. Machiels, Y. Bang, A. Italiano, 2021, Clinical Cancer Research.

A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors

C. Massard, K. Benhadji, S. Pant, 2022, Cancer Chemotherapy and Pharmacology.

Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.

M. Hurwitz, M. Sznol, A. Balar, 2022, European urology.

LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial

R. Carvajal, A. Dowlati, O. Hamid, 2021, Investigational New Drugs.

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

Y. Bang, A. Italiano, A. Patnaik, 2020, Clinical Cancer Research.

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors

A. Italiano, W. Tap, J. Merchan, 2021, Investigational New Drugs.

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

T. Doman, M. Morris, J. Durack, 2020, Clinical Cancer Research.

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

M. Saif, E. Chiorean, J. Kauh, 2016, Cancer Chemotherapy and Pharmacology.

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

N. Vélez de Mendizábal, Y. Bang, J. Harding, 2021, Clinical Cancer Research.

A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

R. Sullivan, K. Flaherty, G. Shapiro, 2019, Molecular Cancer Therapeutics.

Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).

M. Morris, H. McArthur, C. Klebanoff, 2019, Journal of Clinical Oncology.

A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors.

H. Rugo, R. Carvajal, A. Dowlati, 2017 .

Abstract CT018: Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents

Y. Bang, A. Patnaik, J. Bendell, 2018, Clinical Trials.

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

M. Hurwitz, M. Sznol, A. Balar, 2022, Journal for ImmunoTherapy of Cancer.

Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab) LY3022856/IMC-3C5 (3C5).

E. Chiorean, J. Kauh, B. O'Neil, 2015 .